Renal Contributions in the Pathophysiology and Neuropathological Substrates Shared by Chronic Kidney Disease and Alzheimer's Disease

Overview

Journal Brain Sci

Publisher MDPI

Date 2020 Aug 23

PMID 32824404

Citations 15

Authors

Gabriela Dumitrita Stanciu

Daniela Carmen Ababei

Veronica Bild

Walther Bild

Luminita Paduraru

Mihai Marius Gutu

Bogdan-Ionel Tamba

Affiliations

Soon will be listed here.

Abstract

Chronic kidney disease and Alzheimer's disease are chronic conditions highly prevalent in elderly communities and societies, and a diagnosis of them is devastating and life changing. Demanding therapies and changes, such as non-compliance, cognitive impairment, and non-cognitive anomalies, may lead to supplementary symptoms and subsequent worsening of well-being and quality of life, impacting the socio-economic status of both patient and family. In recent decades, additional hypotheses have attempted to clarify the connection between these two diseases, multifactorial in their nature, but even so, the mechanisms behind this link are still elusive. In this paper, we sought to highlight the current understanding of the mechanisms for cognitive decline in patients with these concurrent pathologies and provide insight into the relationship between markers related to these disease entities and whether the potential biomarkers for renal function may be used for the diagnosis of Alzheimer's disease. Exploring detailed knowledge of etiologies, heterogeneity of risk factors, and neuropathological processes associated with these conditions opens opportunities for the development of new therapies and biomarkers to delay or slow their progression and validation of whether the setting of chronic kidney disease could be a potential determinant for cognitive damage in Alzheimer's disease.

Citing Articles

Association of frailty and serum neurofilament light chain levels: the mediating role of estimated glomerular filtration rate.

Yang W, Huang S, Xiao H, Tao P, Cai S Front Aging Neurosci. 2024; 16:1475505.

PMID: 39463817 PMC: 11502322. DOI: 10.3389/fnagi.2024.1475505.

Identification of common biomarkers in diabetic kidney disease and cognitive dysfunction using machine learning algorithms.

Peng J, Yang S, Zhou C, Qin C, Fang K, Tan Y Sci Rep. 2024; 14(1):22057.

PMID: 39333211 PMC: 11436791. DOI: 10.1038/s41598-024-72327-w.

A nomogram for predicting risk of death during hospitalization in elderly patients with Alzheimer's disease at the time of admission.

Yao K, Wang J, Ma B, He L, Zhao T, Zou X Front Neurol. 2023; 14:1093154.

PMID: 36873432 PMC: 9978216. DOI: 10.3389/fneur.2023.1093154.

Pathogenesis of Chronic Kidney Disease Is Closely Bound up with Alzheimer's Disease, Especially via the Renin-Angiotensin System.

Ma K, Zheng Z, Meng Y J Clin Med. 2023; 12(4).

PMID: 36835994 PMC: 9966558. DOI: 10.3390/jcm12041459.

An Association between Insulin Resistance and Neurodegeneration in Zebrafish Larval Model ().

Md Razip N, Noor S, Norazit A, Nordin N, Sakeh N, Khazaai H Int J Mol Sci. 2022; 23(15).

PMID: 35955446 PMC: 9368350. DOI: 10.3390/ijms23158290.

References

Karin M, Greten F . NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005; 5(10):749-59. DOI: 10.1038/nri1703. View

Liyanage T, Ninomiya T, Jha V, Neal B, Patrice H, Okpechi I . Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015; 385(9981):1975-82. DOI: 10.1016/S0140-6736(14)61601-9. View

Muramatsu T, Matsushita S, Arai H, Sasaki H, Higuchi S . Alpha 1-antichymotrypsin gene polymorphism and risk for Alzheimer's disease. J Neural Transm (Vienna). 1996; 103(10):1205-10. DOI: 10.1007/BF01271205. View

Tian X, Guo X, Xia X, Yu H, Li X, Jiang A . The comparison of cognitive function and risk of dementia in CKD patients under peritoneal dialysis and hemodialysis: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(6):e14390. PMC: 6380759. DOI: 10.1097/MD.0000000000014390. View

Santos C, Snyder P, Wu W, Zhang M, Echeverria A, Alber J . Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimers Dement (Amst). 2017; 7:69-87. PMC: 5328683. DOI: 10.1016/j.dadm.2017.01.005. View

Rapa S, Di Iorio B, Campiglia P, Heidland A, Marzocco S . Inflammation and Oxidative Stress in Chronic Kidney Disease-Potential Therapeutic Role of Minerals, Vitamins and Plant-Derived Metabolites. Int J Mol Sci. 2020; 21(1). PMC: 6981831. DOI: 10.3390/ijms21010263. View

Amdur R, Feldman H, Gupta J, Yang W, Kanetsky P, Shlipak M . Inflammation and Progression of CKD: The CRIC Study. Clin J Am Soc Nephrol. 2016; 11(9):1546-1556. PMC: 5012490. DOI: 10.2215/CJN.13121215. View

Butterfield D, Reed T, Newman S, Sultana R . Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med. 2007; 43(5):658-77. PMC: 2031860. DOI: 10.1016/j.freeradbiomed.2007.05.037. View

Neirynck N, Vanholder R, Schepers E, Eloot S, Pletinck A, Glorieux G . An update on uremic toxins. Int Urol Nephrol. 2012; 45(1):139-50. DOI: 10.1007/s11255-012-0258-1. View

10.

Scherzer C, Offe K, Gearing M, Rees H, Fang G, Heilman C . Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol. 2004; 61(8):1200-5. DOI: 10.1001/archneur.61.8.1200. View

11.

Bonelli R, Cummings J . Frontal-subcortical dementias. Neurologist. 2008; 14(2):100-7. DOI: 10.1097/NRL.0b013e31815b0de2. View

12.

Cermik T, Kaya M, Ugur-Altun B, Bedel D, Berkarda S, Yigitbasi O . Regional cerebral blood flow abnormalities in patients with primary hyperparathyroidism. Neuroradiology. 2007; 49(4):379-85. DOI: 10.1007/s00234-006-0198-5. View

13.

Xiang Y, Bu X, Liu Y, Zhu C, Shen L, Jiao S . Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease. Acta Neuropathol. 2015; 130(4):487-99. PMC: 4575389. DOI: 10.1007/s00401-015-1477-1. View

14.

Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E . Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging. 2008; 31(3):357-67. DOI: 10.1016/j.neurobiolaging.2008.03.027. View

15.

Block G, Klassen P, Lazarus J, Ofsthun N, Lowrie E, Chertow G . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15(8):2208-18. DOI: 10.1097/01.ASN.0000133041.27682.A2. View

16.

Harciarek M, Biedunkiewicz B, Lichodziejewska-Niemierko M, Debska-Slizien A, Rutkowski B . Cognitive performance before and after kidney transplantation: a prospective controlled study of adequately dialyzed patients with end-stage renal disease. J Int Neuropsychol Soc. 2009; 15(5):684-94. DOI: 10.1017/S1355617709990221. View

17.

Sarnak M, Tighiouart H, Scott T, Lou K, Sorensen E, Giang L . Frequency of and risk factors for poor cognitive performance in hemodialysis patients. Neurology. 2013; 80(5):471-80. PMC: 3590049. DOI: 10.1212/WNL.0b013e31827f0f7f. View

18.

Qosa H, AbuAsal B, Romero I, Weksler B, Couraud P, Keller J . Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. Neuropharmacology. 2014; 79:668-78. PMC: 3965363. DOI: 10.1016/j.neuropharm.2014.01.023. View

19.

Shanahan C, Crouthamel M, Kapustin A, Giachelli C . Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011; 109(6):697-711. PMC: 3249146. DOI: 10.1161/CIRCRESAHA.110.234914. View

20.

Smith A, Refsum H, Bottiglieri T, Fenech M, Hooshmand B, McCaddon A . Homocysteine and Dementia: An International Consensus Statement. J Alzheimers Dis. 2018; 62(2):561-570. PMC: 5836397. DOI: 10.3233/JAD-171042. View